share_log

TCR2 Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-THE K2 Principal Fund, L.P.(5.05%),K2 Genpar 2017 Inc.(5.05%), etc.

TCR2 Therapeutics | SC 13G:超过5%持股股东披露文件-THE K2 Principal Fund, L.P.(5.05%),K2 Genpar 2017 Inc.(5.05%)等

2022/08/31 18:13
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息